Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma.

Agache I, Song Y, Rocha C, Beltran J, Posso M, Steiner C, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M.

Allergy. 2020 Mar 10. doi: 10.1111/all.14268. [Epub ahead of print]

PMID:
32154939
2.

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma.

Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I, Alonso-Coello P, Akdis C, Akdis M, Canonica W, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M.

Allergy. 2020 Feb 16. doi: 10.1111/all.14235. [Epub ahead of print]

PMID:
32064642
3.

Reply.

Corren J.

J Allergy Clin Immunol Pract. 2020 Feb;8(2):822. doi: 10.1016/j.jaip.2019.11.025. No abstract available.

PMID:
32037117
4.

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma.

Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, Palomares O, Jutel M.

Allergy. 2020 Feb 8. doi: 10.1111/all.14221. [Epub ahead of print]

PMID:
32034960
5.

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.

Castro M, Rabe KF, Corren J, Pavord ID, Katelaris CH, Tohda Y, Zhang B, Rice MS, Maroni J, Rowe P, Pirozzi G, Amin N, Ruddy M, Akinlade B, Graham NMH, Teper A.

ERJ Open Res. 2020 Jan 27;6(1). pii: 00204-2019. doi: 10.1183/23120541.00204-2019. eCollection 2020 Jan.

6.

TSLP: from allergy to cancer.

Corren J, Ziegler SF.

Nat Immunol. 2019 Dec;20(12):1603-1609. doi: 10.1038/s41590-019-0524-9. Epub 2019 Nov 19. Review.

PMID:
31745338
7.

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial.

Menzies-Gow A, Corren J, Bel EH, Maspero J, Heaney LG, Gurnell M, Wessman P, Martin UJ, Siddiqui S, Garcia Gil E.

ERJ Open Res. 2019 Sep 25;5(3). pii: 00009-2019. doi: 10.1183/23120541.00009-2019. eCollection 2019 Jul.

8.

Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.

Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan AH, Kamat S, Maroni J, Rowe P, Lu Y, Amin N, Pirozzi G, Ruddy M, Graham NMH, Teper A.

J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526. doi: 10.1016/j.jaip.2019.08.050. Epub 2019 Sep 12.

9.

Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.

Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, Peters AT, Pavord ID, Ford LB, Sher L, Rabe KF, Rice MS, Rowe P, Lu Y, Harel S, Jagerschmidt A, Khan AH, Kamat S, Pirozzi G, Amin N, Ruddy M, Graham NMH, Mannent LP, Teper A.

J Allergy Clin Immunol Pract. 2020 Feb;8(2):527-539.e9. doi: 10.1016/j.jaip.2019.07.016. Epub 2019 Jul 24.

10.

New Targeted Therapies for Uncontrolled Asthma.

Corren J.

J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1394-1403. doi: 10.1016/j.jaip.2019.03.022. Review.

PMID:
31076057
11.

Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history.

Corren J, Castro M, Ford LB, Bernstein JA, Jayawardena S, Maroni J, Rowe P, Amin N, Pirozzi G, Graham NMH, Khan A, Eckert L, Teper A.

Ann Allergy Asthma Immunol. 2019 Aug;123(2):222-224.e1. doi: 10.1016/j.anai.2019.04.028. Epub 2019 May 8. No abstract available.

12.

Conjunctivitis in dupilumab clinical trials.

Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A.

Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7.

13.

Advancing the Care of Severe Asthma: Differential Diagnosis, Multidisciplinary Management, and Patient Engagement.

Corren J, Yawn BP.

Am J Med. 2019 Feb 20. pii: S0002-9343(19)30146-9. doi: 10.1016/j.amjmed.2019.02.002. [Epub ahead of print] No abstract available.

PMID:
30794771
14.

How Important Is Adherence to Inhaled Medications Before Starting a Biologic Therapy for Asthma?

Corren J, Panettieri RA Jr.

J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1578-1579. doi: 10.1016/j.jaip.2018.07.007. No abstract available.

PMID:
30197071
15.

Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma.

Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbé A, Taniou C, Mahajan P, Teper A, Pirozzi G, Eckert L.

Ann Allergy Asthma Immunol. 2019 Jan;122(1):41-49.e2. doi: 10.1016/j.anai.2018.08.005. Epub 2018 Aug 21.

16.

Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab.

Ke X, Kavati A, Wertz D, Huang Q, Wang L, Willey VJ, Stephenson JJ, Ortiz B, Panettieri RA Jr,, Corren J.

Clin Ther. 2018 Jul;40(7):1140-1158.e4. doi: 10.1016/j.clinthera.2018.05.014. Epub 2018 Jul 23.

PMID:
30049502
17.

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A.

N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.

18.

Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials.

Corren J, Kavati A, Ortiz B, Vegesna A, Colby JA, Ruiz K, Panettieri RA Jr.

Curr Med Res Opin. 2018 Jan;34(1):65-80. doi: 10.1080/03007995.2017.1395734. Epub 2017 Nov 10.

PMID:
29057669
19.

Tezepelumab in Adults with Uncontrolled Asthma.

Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R.

N Engl J Med. 2017 Sep 7;377(10):936-946. doi: 10.1056/NEJMoa1704064. Erratum in: N Engl J Med. 2019 May 23;380(21):2082.

20.

Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.

Corren J, Kavati A, Ortiz B, Colby JA, Ruiz K, Maiese BA, Cadarette SM, Panettieri RA Jr.

Allergy Asthma Proc. 2017 Jul 1;38(4):250-263. doi: 10.2500/aap.2017.38.4067. Epub 2017 Jun 19. Review.

PMID:
28631599
21.

Inflammatory Disorders Associated with Allergy: Overview of Immunopathogenesis and Implications for Treatment.

Corren J.

Immunol Allergy Clin North Am. 2017 May;37(2):233-246. doi: 10.1016/j.iac.2017.01.001. Epub 2017 Mar 3. Review.

PMID:
28366474
22.

Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma.

Chipps BE, Corren J, Israel E, Katial R, Lang DM, Panettieri RA Jr, Peters SP, Farrar JR.

Ann Allergy Asthma Immunol. 2017 Feb;118(2):133-142.e3. doi: 10.1016/j.anai.2016.12.010. Review.

PMID:
28153079
23.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A.

Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27.

PMID:
27130691
24.

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.

Corren J, Weinstein S, Janka L, Zangrilli J, Garin M.

Chest. 2016 Oct;150(4):799-810. doi: 10.1016/j.chest.2016.03.018. Epub 2016 Mar 25.

25.

Remodeling in Allergic Rhinitis. Adding New Data to an Old Debate.

Corren J, Togias A.

Am J Respir Crit Care Med. 2015 Dec 15;192(12):1403-4. doi: 10.1164/rccm.201510-1937ED. No abstract available.

26.

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K.

Thorax. 2015 Aug;70(8):748-56. doi: 10.1136/thoraxjnl-2014-206719. Epub 2015 May 22.

27.

Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform(®)) for the treatment of asthma.

Tan RA, Corren J.

Drug Des Devel Ther. 2014 Sep 30;8:1555-61. doi: 10.2147/DDDT.S36556. eCollection 2014. Review.

28.

Exacerbation-prone asthma--intrinsic to severe disease or a unique phenotype?

Corren J.

Clin Exp Allergy. 2014 Feb;44(2):152-3. doi: 10.1111/cea.12256. No abstract available.

PMID:
24447078
29.

Role of interleukin-13 in asthma.

Corren J.

Curr Allergy Asthma Rep. 2013 Oct;13(5):415-20. doi: 10.1007/s11882-013-0373-9. Review.

PMID:
24026573
30.
31.

Anti-interleukin-13 antibody therapy for asthma: one step closer.

Corren J.

Eur Respir J. 2013 Feb;41(2):255-6. doi: 10.1183/09031936.00124212. No abstract available.

32.

Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.

Corren J, Mansfield LE, Pertseva T, Blahzko V, Kaiser K.

Respir Med. 2013 Feb;107(2):180-95. doi: 10.1016/j.rmed.2012.10.025. Epub 2012 Dec 25.

33.

Inhibition of interleukin-5 for the treatment of eosinophilic diseases.

Corren J.

Discov Med. 2012 Apr;13(71):305-12. Review.

34.

Omalizumab in the treatment of asthma.

Tan R, Corren J.

Expert Rev Respir Med. 2011 Dec;5(6):747-56. doi: 10.1586/ers.11.73. Review.

PMID:
22082161
35.

Anti-interleukin-5 antibody therapy in asthma and allergies.

Corren J.

Curr Opin Allergy Clin Immunol. 2011 Dec;11(6):565-70. doi: 10.1097/ACI.0b013e32834c3d30. Review.

PMID:
21971335
36.

Lebrikizumab treatment in adults with asthma.

Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG.

N Engl J Med. 2011 Sep 22;365(12):1088-98. doi: 10.1056/NEJMoa1106469. Epub 2011 Aug 3.

37.

The relationship of rhinitis and asthma, sinusitis, food allergy, and eczema.

Tan RA, Corren J.

Immunol Allergy Clin North Am. 2011 Aug;31(3):481-91. doi: 10.1016/j.iac.2011.05.010.

PMID:
21737039
38.

Safety of omalizumab in asthma.

Tan RA, Corren J.

Expert Opin Drug Saf. 2011 May;10(3):463-71. doi: 10.1517/14740338.2011.563840. Epub 2011 Mar 15. Review.

PMID:
21401438
39.

Cytokine inhibition in severe asthma: current knowledge and future directions.

Corren J.

Curr Opin Pulm Med. 2011 Jan;17(1):29-33. doi: 10.1097/MCP.0b013e3283413105. Review.

PMID:
21330823
40.

Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge.

Corren J, Wood RA, Patel D, Zhu J, Yegin A, Dhillon G, Fish JE.

J Allergy Clin Immunol. 2011 Feb;127(2):398-405. doi: 10.1016/j.jaci.2010.09.043.

PMID:
21281870
41.

Efficacy and safety of budesonide and formoterol in asthma.

Corren J.

Hosp Pract (1995). 2009 Dec;37(1):162-3. doi: 10.3810/hp.2009.12.272. No abstract available.

PMID:
20877186
42.

Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids.

Weinstein SF, Corren J, Murphy K, Nolte H, White M; Study Investigators of P04431.

Allergy Asthma Proc. 2010 Jul-Aug;31(4):280-9. doi: 10.2500/aap.2010.31.3381. Epub 2010 Aug 3.

PMID:
20687982
43.

Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma.

Zeidler M, Corren J, Tashkin DP.

Curr Med Res Opin. 2010 Jun;26(6):1295-305. doi: 10.1185/03007991003701152. Review.

PMID:
20370376
44.

Meeting the obligation to balance bioethics and clinical trial design in asthma.

Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, Anderson WH, Emmett AH, Ortega HA.

Am J Respir Crit Care Med. 2010 Apr 1;181(7):648-50. doi: 10.1164/rccm.200912-1891ED. No abstract available.

PMID:
20335380
45.

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma.

Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, Lin SL.

Am J Respir Crit Care Med. 2010 Apr 15;181(8):788-96. doi: 10.1164/rccm.200909-1448OC. Epub 2010 Jan 7.

PMID:
20056900
46.

Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate.

Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, Anderson WH, Emmett AH, Ortega HG.

Am J Respir Crit Care Med. 2010 Apr 1;181(7):676-87. doi: 10.1164/200809-1511OC. Epub 2009 Nov 12.

PMID:
19910613
48.

Criteria to screen for chronic sinonasal disease.

Dixon AE, Sugar EA, Zinreich SJ, Slavin RG, Corren J, Naclerio RM, Ishii M, Cohen RI, Brown ED, Wise RA, Irvin CG; American Lung Association-Asthma Clinical Research Centers.

Chest. 2009 Nov;136(5):1324-1332. doi: 10.1378/chest.08-1983. Epub 2009 Jul 6.

49.

Mometasone furoate in the management of asthma: a review.

Tan RA, Corren J.

Ther Clin Risk Manag. 2008 Dec;4(6):1201-8.

50.

Safety and tolerability of omalizumab.

Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P.

Clin Exp Allergy. 2009 Jun;39(6):788-97. doi: 10.1111/j.1365-2222.2009.03214.x. Epub 2009 Mar 17. Review.

PMID:
19302249

Supplemental Content

Loading ...
Support Center